Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
The newfound energy and mobility from tirzepatide treatment allow for more active lifestyles, which enhances overall well-being
If travelling to remote areas without reliable refrigeration, consult your pharmacist about the maximum duration your specific GLP-1 product can remain at room temperature, and plan your medication supply accordingly
Ind Crop Prod 189:115763 Marino D, Dunand C, Puppo A, Pauly N (2012) A burst of plant NADPH oxidases
Your therapist at CPR Physical Therapy+Performance will also focus particularly on gaining back those ranges of movement which are commonly lost after this type of surgery
